All news

B. Riley lifts Eton Pharmaceuticals price target to $81

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

B. Riley Financial raised its price target on Eton Pharmaceuticals (NASDAQ:ETON) to $81 from $70 while keeping a "buy" rating, implying upside of more than 20%. The move follows quarterly results in which the specialty pharmaceutical company beat analyst expectations with EPS of $0.50 and revenue of $57.93 million.

Read original source

RILYZ company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.